AU2022227673A1 - Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis - Google Patents

Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis Download PDF

Info

Publication number
AU2022227673A1
AU2022227673A1 AU2022227673A AU2022227673A AU2022227673A1 AU 2022227673 A1 AU2022227673 A1 AU 2022227673A1 AU 2022227673 A AU2022227673 A AU 2022227673A AU 2022227673 A AU2022227673 A AU 2022227673A AU 2022227673 A1 AU2022227673 A1 AU 2022227673A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
formula
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022227673A
Other languages
English (en)
Other versions
AU2022227673A9 (en
Inventor
Ida ARONCHIK
Roxxana Valeria BELTRAN VALENCIA
Maria Soraya Carrancio Anton
Henry H. Chang
Shodeinde COKER
Sharmila Das
Oriana ESPOSITO
Ellen Hope Filvaroff
Carla GUARINOS MARHUENDA
Bishoy HANNA
Yu Liu
Zariana NIKOLOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of AU2022227673A1 publication Critical patent/AU2022227673A1/en
Publication of AU2022227673A9 publication Critical patent/AU2022227673A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
AU2022227673A 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis Pending AU2022227673A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21382163.0 2021-02-25
EP21382163 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US63/232,866 2021-08-13
US202263297098P 2022-01-06 2022-01-06
US63/297,098 2022-01-06
PCT/US2022/017678 WO2022182857A1 (en) 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis

Publications (2)

Publication Number Publication Date
AU2022227673A1 true AU2022227673A1 (en) 2023-08-17
AU2022227673A9 AU2022227673A9 (en) 2024-09-19

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022227673A Pending AU2022227673A1 (en) 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis

Country Status (12)

Country Link
US (2) US12357621B2 (https=)
EP (1) EP4297750A1 (https=)
JP (1) JP2024507938A (https=)
KR (1) KR20230148208A (https=)
AU (1) AU2022227673A1 (https=)
CA (1) CA3206708A1 (https=)
CL (1) CL2023002497A1 (https=)
IL (1) IL304697A (https=)
MX (1) MX2023009858A (https=)
TW (1) TW202302095A (https=)
WO (1) WO2022182857A1 (https=)
ZA (1) ZA202307538B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022261204A1 (en) 2021-06-08 2022-12-15 The Regents Of The University Of California Anticancer compounds
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR102457145B1 (ko) * 2013-12-24 2022-10-19 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 트리시클릭 화합물
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3355922A2 (en) * 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
US12391676B2 (en) * 2018-09-07 2025-08-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-JAK2 inhibitors
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
FI3908281T3 (fi) * 2019-01-09 2024-10-01 Celgene Corp Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
PT4161528T (pt) * 2020-06-03 2026-01-23 Incyte Corp Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas

Also Published As

Publication number Publication date
IL304697A (en) 2023-09-01
US12357621B2 (en) 2025-07-15
CA3206708A1 (en) 2022-09-01
WO2022182857A1 (en) 2022-09-01
TW202302095A (zh) 2023-01-16
AU2022227673A9 (en) 2024-09-19
EP4297750A1 (en) 2024-01-03
ZA202307538B (en) 2026-01-28
US20220265617A1 (en) 2022-08-25
US20250367174A1 (en) 2025-12-04
CL2023002497A1 (es) 2024-01-12
MX2023009858A (es) 2023-09-12
KR20230148208A (ko) 2023-10-24
JP2024507938A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
US12357621B2 (en) BET inhibitors as a treatment for myelofibrosis
EP1261322B1 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP2637664B1 (en) Compositions and methods of treating pulmonary hypertension
AU2008254273B2 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
JP2024012493A (ja) 消化管間質腫瘍の治療のための併用療法
CA2525366A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20090312290A1 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
US10576050B2 (en) Methods and compositions for treatment of cancer
KR20080003895A (ko) 아밀로이드증 치료용 제제 및 치료 방법
US20090048173A1 (en) Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
US20150051236A1 (en) Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
EA050366B1 (ru) Применение ингибиторов bet отдельно или в комбинации с федратинибом или с руксолитинибом для лечения гематологического злокачественного новообразования, такого как миелофиброз
CN117615759A (zh) Bet抑制剂单独或者与菲卓替尼或芦可替尼组合用于治疗血液恶性肿瘤如骨髓纤维化的用途
KR20240144146A (ko) Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
WO2025078276A1 (en) Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma
EP1441717B1 (en) Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog
EP1391203A1 (en) Antitumor agents
WO2025056055A1 (zh) 新一代egfr抑制剂单药或联合使用在制备肿瘤疾病的药物中的应用
CN121041280A (zh) 亚氨基砜类化合物治疗淋巴瘤的用途
WO2007010014A2 (en) Compositions for treatment of systemic mastocytosis
HK1188716A (en) Compositions and methods of treating pulmonary hypertension
HK1188716B (en) Compositions and methods of treating pulmonary hypertension
HK1227306A1 (en) Compositions and methods of treating pulmonary hypertension

Legal Events

Date Code Title Description
SREP Specification republished